Anges & Vasomune Therapeutics Enter Agreement For AV-001

Nov 25 (Reuters) - AnGes Inc (4563.T) :* ANGES INC: CO & VASOMUNE THERAPEUTICS ENTER AGREEMENT TO EXPAND RESEARCH INDICATIONS FOR TIE2 RECEPTOR AGONIST PEGEVONGITIDE (AV-001) Source text: Further company coverage: (4563.T)